AstraZeneca's $100M expansion of Boston facility to boost cancer/antbiotics R&D
Anglo-Swedish drug major AstraZeneca has made a $100.0 million investment to strategically boost work in the infectious disease area and continue the incremental growth in cancer research at its R&D center near Boston, Massachusetts, USA. The expansion of the facility will accommodate up to 100 additional researchers who would join over 400 existing scientists in these two disease areas.
"This investment will significantly boost our research capabilities in two critical areas of medical need, and two areas where we have tremendous heritage" said David Brennan, AstraZeneca's chief executive. Jan Lundberg, the firm's executive vice president, global discovery research, added that "infectious disease is becoming more prevalent and problematic to patients and health care providers, placing a heavy burden on our health care systems."
Global infectious disease burden rising
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze